Lena A, Foffi E, Agostini M, Mancini M, Annicchiarico-Petruzzelli M, Aberdam D
Cell Cycle. 2021; 20(22):2428-2441.
PMID: 34763601
PMC: 8794505.
DOI: 10.1080/15384101.2021.1985772.
Timotheadou E, Kalogeras K, Koliou G, Wirtz R, Zagouri F, Koutras A
Transl Oncol. 2017; 10(4):589-598.
PMID: 28666187
PMC: 5491451.
DOI: 10.1016/j.tranon.2017.05.006.
El-Amm J, Aragon-Ching J
Clin Med Insights Oncol. 2016; 10(Suppl 1):11-9.
PMID: 27042152
PMC: 4807885.
DOI: 10.4137/CMO.S30751.
Boron D, Agnieszka S, Daniel K, Anna B, Adam K
Eur J Med Res. 2014; 19:69.
PMID: 25510225
PMC: 4311426.
DOI: 10.1186/s40001-014-0069-1.
Ray P, Stacer A, Fenner J, Cavnar S, Meguiar K, Brown M
Oncogene. 2014; 34(16):2043-51.
PMID: 24909174
PMC: 4261050.
DOI: 10.1038/onc.2014.157.
Inflammatory and immune pathways in the pathogenesis of periodontal disease.
Cekici A, Kantarci A, Hasturk H, Van Dyke T
Periodontol 2000. 2013; 64(1):57-80.
PMID: 24320956
PMC: 4500791.
DOI: 10.1111/prd.12002.
Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines.
Labovsky V, Fernandez Vallone V, Martinez L, Otaegui J, Chasseing N
Cancer Cell Int. 2012; 12(1):29.
PMID: 22709548
PMC: 3478192.
DOI: 10.1186/1475-2867-12-29.
Oral inflammatory diseases and systemic inflammation: role of the macrophage.
Hasturk H, Kantarci A, Van Dyke T
Front Immunol. 2012; 3:118.
PMID: 22623923
PMC: 3353263.
DOI: 10.3389/fimmu.2012.00118.
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients.
Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A
PLoS One. 2011; 6(4):e19234.
PMID: 21559440
PMC: 3084800.
DOI: 10.1371/journal.pone.0019234.
Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
Virk M, Petrigliano F, Liu N, Chatziioannou A, Stout D, Kang C
Bone. 2008; 44(1):160-7.
PMID: 18929692
PMC: 2657045.
DOI: 10.1016/j.bone.2008.09.009.
RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.
Ignatoski K, Escara-Wilke J, Dai J, Lui A, Dougall W, Daignault S
Prostate. 2008; 68(8):820-9.
PMID: 18324676
PMC: 7480006.
DOI: 10.1002/pros.20744.
Oral mucosal dendritic cells and periodontitis: many sides of the same coin with new twists.
Cutler C, Teng Y
Periodontol 2000. 2007; 45:35-50.
PMID: 17850447
PMC: 2828688.
DOI: 10.1111/j.1600-0757.2007.00222.x.
Interleukin-10 inhibits gram-negative-microbe-specific human receptor activator of NF-kappaB ligand-positive CD4+-Th1-cell-associated alveolar bone loss in vivo.
Zhang X, Teng Y
Infect Immun. 2006; 74(8):4927-31.
PMID: 16861684
PMC: 1539589.
DOI: 10.1128/IAI.00491-06.
Gamma interferon positively modulates Actinobacillus actinomycetemcomitans-specific RANKL+ CD4+ Th-cell-mediated alveolar bone destruction in vivo.
Teng Y, Mahamed D, Singh B
Infect Immun. 2005; 73(6):3453-61.
PMID: 15908374
PMC: 1111859.
DOI: 10.1128/IAI.73.6.3453-3461.2005.
